Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701521 | 1.00 | TRPM2 (0.33) | TRPM2CNR1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL13513395 | 0.90 | TRPM2 (0.33) | TRPM2SMN1; SMN2CYP11B1CYP11B2S1PR1 | |
| SCHEMBL702910 | 0.90 | HCRTR1 (0.35) | TRPM2SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL702911 | 0.90 | HCRTR1 (0.35) | TRPM2SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL701349 | 0.89 | PTGDR2 (0.34) | CYP2C9DHODH | |
| SCHEMBL701350 | 0.89 | PTGDR2 (0.34) | CYP2C9DHODH | |
| SCHEMBL701692 | 0.85 | ALDH1A1 (0.33) | TRPM2SMN1; SMN2USP2MAPTLMNA | |
| SCHEMBL701693 | 0.85 | ALDH1A1 (0.33) | TRPM2SMN1; SMN2USP2MAPTLMNA | |
| SCHEMBL16494495 | 0.83 | TRPM2 (0.37) | TRPM2SMN1; SMN2CYP11B1CYP11B2DHODH | |
| SCHEMBL702305 | 0.82 | F10 (0.36) | CNR1SMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | claimed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | claimed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | claimed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | TRPM2 1670/4885CNR1 244/4885SMN1; SMN2 4478/4885 |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | TRPM2 1670/4885CNR1 244/4885SMN1; SMN2 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.